Masimo (NASDAQ: MASI), the inventor of Measure-Through Motion and Low
Perfusion ™ for pulse oximetry, today announced its US $ 1,000,000
Extended performance guarantee, which pulse oximetry with Masimo SET ®
All Pulse Oximeter Nellcor (part of Covidien, Medtronic now)
will surpass. The guarantee states in the event that with Masimo SET
proven not better performance
can be provided, as with any of Nellcor pulse oximeter
including the three for which Covidien obtaining a
FDA 510 (k) clearance has reported with motion claims, Masimo up to
Will pay $ 1,000,000 to enable a clinic this pulse oximetry
can acquire.
"As a medical technology company we have in our opinion the
Duty honestly and openly to advertise because it is ultimately for the welfare of the
Patient goes. We are still confused by the misleading
Marketing strategy of our competitor, "said Joe Kiani, founder
and CEO of Masimo. "We are troubled, out the customers astray
be, and hope that they, inspired by our guarantee in question
ask what is told them there, and the performance of
Check technologies itself and evaluate. "
Apart from the extension of the one-million-dollar guarantee Masimo has its
Website updated. The company here in detail on each of the
inaccurate and misleading assertions a: http://www.masimo.com/nellcorfiction/
Masimo gives each clinic four promises that Covidien has not to
give was ready:
- We are the superior performance of Masimo SET pulse oximetry with ®
prove in direct comparison with Nellcor.
We are independent and objective scientific evidence of
Provide superiority of Masimo SET ® against Nellcor,
and evidence that Masimo SET ® clinician in
Support improving their clinical and financial results.
We speak very scientific direct comparisons of
Pulse Oximetry Masimo SET ® with the Nellcor under
demanding conditions of automatic data capture.
We are very confident that an objective comparison
clinical superiority of Masimo SET ® will show and
continue to provide a performance guarantee in the amount of
1,000,000 US dollars.
Please note: This offer is only for hospitals that plan their
Pulse oximetry hospital campus to bring up to date standard. Important
Details, terms and conditions for the competition can be found
under http://www.masimo.com/1millionrules.htm.
MasimoInnovates | #Masimo
About Masimo
Masimo (NASDAQ: MASI) is the international
Leader in innovative, non-invasive
Monitoring technologies to patient care significantly
is improved, to help solve "unsolvable" problems. In
1995, the company debuted Measure-Through-Motion the
and Low-Perfusion pulse oximetry before, known as Masimo SET®, with the
False alarms virtually no longer occur. The possibilities
Pulse oximetry, clinicians in the discovery of life-threatening events
support, were expanded so. In 2005, Masimo introduced the
Technology rainbow ® Pulse CO-Oximetry ™ out. This was a
non-invasive, continuous monitoring of components of blood
possible what previously required invasive procedures:
Hemoglobin content (SpHb®), oxygen content (SPOC ™), carboxyhemoglobin
(SpCO®), methemoglobin (SpMet®), PVI®, and perfusion index (PI), and
Measurement of motion with SpO2 and pulse rate. In 2008 presented
Masimo Patient SafetyNet ™, the front, a wireless
Notification system for remote monitoring for clinicians. Clinics
are thus able to avoid preventable deaths and injuries,
such as may occur as a result of failed bailouts. In The
2009 Masimo introduced before the rainbow® Acoustic Monitoring ™, the
world's first commercially available technology for non-invasive
and continuous monitoring of acoustic respiration rate (RRa ™). The
Founded in 1989, Masimo follows his mission "Improving
Patient Outcome and Reducing Cost of Care ... by Taking Noninvasive
Monitoring to New Sites and Applications® "(" improving
Quality of life and reduction of maintenance costs - by
Enabling new locations and applications for non-invasive
Monitoring "). Additional information about Masimo and its products
see www.masimo.com.
MasimoInnovates
Forward-Looking Statements This release contains
"Forward-looking statements" within the meaning of Section 27A of the Securities
Act of 1933, Section 21E of the Securities Exchange Act of 1934 and
within the meaning of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are based on current expectations about
future, relevant for our events, and are subject
Risks and uncertainties that are difficult to make predictions about the
and many of which are beyond our control. The
Actual results could therefore result of various risk factors
related MightySat significantly and in a negative way by the
differ in our forward-looking statements. These include
our belief in the groundbreaking potential of Masimo
SET® pulse oximetry for measurement during motion and low perfusion,
and other factors discussed in the section entitled "Risk Factors" of the current
filed by us with the Securities and Exchange Commission ("SEC")
Reports are described. These are available for free on the site
the SEC at www.sec.gov.
Although we believe that our forward-looking statements
reproduced expectations are realistic, we do not know whether
our expectations will prove correct. All in
these statements contained in this press release are in their entirety
expressly qualified by the previous warnings. They
are asked not to place undue reliance on these forward-looking
To leave statements, which only apply to the present time. We
assume no obligation to update these statements or in our
contained in the most recent reports filed SEC
To update, revise or explain in more detail the "Risk Factors"
- Whether because of new information, future events or otherwise
Reasons except where it according to applicable securities laws
is prescribed.
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome
and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, rainbow, SpHb, SPOC, SpCO, SpMet, PVI are
Trademarks or registered trademarks of Masimo Corporation.
The initial language in which the original text is published is,
the official, authoritative version. Translations are for
better understanding included. Only the language version that the
Original was published, is legally valid. Straighten therefore
Translations from the original language of publication.
View original version on businesswire.com: http://www.businesswire.com/news/home/20150714005718/de/
No comments:
Post a Comment